An interventional study of Proximal Femoral Guided Growth. and Standard prophylactic treatment for Hips at Risk of Dislocation. in Cerebral Palsy, sponsored by Fundación para la investigación biomética Hospital Infantil Universitario Niño Jesús. Recruiting at 16 sites in Spain. Open to participants aged 3 Years to 8 Years. Per ClinicalTrials.gov, last updated 2025-05-04.
Sponsored by Fundación para la investigación biomética Hospital Infantil Universitario Niño Jesús · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 54 studies in Cerebral Palsy with a site in Spain — 14 open to participants now, 17 under way, 1 of them phase 3. Cerebral Palsy · Spain.
Among the 54 studies in Cerebral Palsy with a site in Spain, this one is the 15th largest by planned enrollment of the 44 interventional ones that give a count, is one of 8 that started in 2024, is one of 37 with no phase, reaches primary completion later than 12 of the 16 other live ones, and was the 47th registered.
1,942 studies on the registry are indexed under Cerebral Palsy; 456 are open to participants now.
Browse Cerebral Palsy studies →14 of the 54 studies in Cerebral Palsy with a site in Spain are open now. Recruiting first, the newest first:
Facultat de ciencies de la Salut Universitat Ramon Llull · Sites in Spain
Ages 18–80
University of Valencia · Sites in Spain
Ages 10–18
Universidade da Coruña · Sites in Spain
Ages 3–8
Universidad de Almeria · Sites in Spain
Ages 2–11 · Healthy volunteers
University of Seville · Sites in Spain
Ages 3–12
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 271 Cerebral Palsy studies recruiting now, 26 (10%) set no upper age limit and 237 (87%) stop at 75 or younger; 256 take children under 18; 53 take healthy volunteers.
This study: 3 Years to 8 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
54 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 2 · Phase 3 6
First in 2011; this study’s year is marked. 8 started in 2024.
This study's planned enrollment of 42 is above the median of 34 across 1,434 interventional studies indexed under Cerebral Palsy.
Median enrollment 32 across the 44 interventional studies, 50 across the 10 observational. Of the 33 that completed or were terminated, 4 (12%) have results posted.
This tab as a report to print or save as PDF → With an account.
14 of 54 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Fundación para la investigación biomética Hospital Infantil Universitario Niño Jesús as lead sponsor.
Fundación para la investigación biomética Hospital Infantil Universitario Niño Jesús has 1 study filed under Cerebral Palsy — fewer than ten, so there is no comparison to draw.
2 of the studies in Cerebral Palsy with a site in Spain that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06438666University of MalagaEffects Obtained at Manual Function After Applying Anodic Transcranial Direct Current Stimulation (tCDS) in Children With Spastic Hemiparetic Cerebral Palsy | 2026-12-23 |
| NCT07745712ABLE Human Motion S.L.Clinical Investigation to Validate the Safety and Performance of the ABLE Kids Device in Pediatric Patients With Neurological Gait Disorders in a Clinical Setting | 2026-12-31 |
Add all 2 to your calendar (.ics) → With an account.
Among the 54 studies in Cerebral Palsy with a site in Spain, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The Guided Growth in Spastic Hip Multicenter Study (GGSH-MC) is a prospective, multicenter, randomized controlled trial that aims to evaluate the mid-term outcomes of Proximal Femoral Guided Growth (PFGG) in children with spastic cerebral palsy (CP) and hips at risk of dislocation (HRD). Hip dislocation is a common and severe complication in children with CP, especially those who are non-ambulatory, with a reported risk of 70-90%.
The trial includes children aged 3 to 8 years with spastic CP and HRD, defined by a migration percentage (MP) between 30% and 60%. Participants will be cluster-randomized by center into two parallel groups:
PFGG involves insertion of a fully threaded cannulated screw across the lateral cortex and proximal femoral epiphysis under fluoroscopic guidance, with the aim of modulating growth to improve hip containment. All patients will also receive standard soft tissue surgery (adductor and/or psoas tenotomies), as clinically indicated.
Follow-up will include clinical, radiographic, and functional assessments at 3 and 6 weeks, and at 6, 12, 18, and 24 months post-intervention. The study will include a 1-year inclusion period and a 2-year follow-up, concluding in October 2027.
Primary outcome measures include radiographic indicators of hip displacement. Secondary outcomes include functional scores, complication rates, and need for further surgery. A total of 42 participants (21 per group) will provide 80% power to detect significant differences at a 0.05 significance level. Analyses will be performed using intention-to-treat principles, with subgroup and multivariate analyses to explore modifying factors.
Cerebral palsy (CP) is the leading cause of severe physical disability in childhood, with a prevalence of 1.6 per 1,000 live births in developed countries. Spastic CP, affecting 75% of patients, often leads to progressive musculoskeletal deformities due to muscle imbalance, particularly around the hip joint. Hip dysplasia is the second most common deformity, and if untreated, can progress to dislocation, especially in non-ambulatory children (GMFCS IV-V), where risk exceeds 70%.
Hip displacement in CP is attributed to spasticity of the adductors and flexors, growth-related deformities such as coxa valga and acetabular dysplasia, and limited weight-bearing. These changes can impair function, sitting tolerance, hygiene, and quality of life. Current strategies emphasize surveillance and early intervention for hips at risk of dislocation (HRD), including soft tissue surgery. However, recurrence remains high, and reconstructive surgery, while effective, is invasive and associated with significant morbidity.
Proximal Femoral Guided Growth (PFGG) is a minimally invasive technique involving medial hemiepiphysiodesis with a cannulated screw to modulate proximal femoral growth and improve containment. Though early outcomes are promising, prospective multicenter evidence is limited.
This study is a prospective, multicenter, randomized controlled trial using cluster randomization by center to compare PFGG + standard treatment versus standard treatment alone. Children aged 3-8 years with spastic CP and HRD (MP 30-60%) will be included. The primary outcome is radiographic containment. Secondary outcomes include functional scores, pain, complications, and reintervention rates. Follow-up spans 24 months.
All surgeries follow a standardized protocol. Postoperative care includes early mobilization, use of hip abduction wedge, and physical therapy. Sample size is calculated for 80% power to detect a difference in dislocation rates, requiring 42 subjects. Data will be collected using standardized CRFs and managed centrally under SEOP oversight. Adverse events will be systematically recorded.
The study has IRB approval and complies with ISO 14155, GDPR, and the Helsinki Declaration. Funding is provided by the 2023 EPOS Research Grant (€10,000). Results will be published regardless of outcome.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participants in this arm will receive Proximal Femoral Guided Growth (PFGG) in addition to standard prophylactic treatment for hips at risk of dislocation (HRD). The standard treatment may include adductor tenotomy (percutaneous or open) and psoas tenotomy (intrapelvic or at the lesser trochanter) as indicated. Surgery will be performed under general anesthesia, and postoperative immobilization will follow institutional protocols, including the use of a hip abduction wedge, knee immobilizers, and ankle-foot orthoses (AFO) as required. Follow-up will include standardized clinical, functional, and radiographic assessments at 3 weeks, 6 weeks, 6 months, 12 months, 18 months, and 24 months postoperatively.
Procedure: Proximal Femoral Guided Growth. · Procedure: Standard prophylactic treatment for Hips at Risk of Dislocation.
Participants in this arm will receive standard prophylactic treatment for HRD without PFGG. This may include adductor and/or psoas tenotomies based on clinical indication, performed under general anesthesia. Postoperative care will be identical to the experimental group, with standard immobilization using a hip abduction wedge, knee immobilizers, and AFOs as needed. The follow-up schedule and outcome assessments will be identical to the experimental group, ensuring consistency in data collection.
Procedure: Standard prophylactic treatment for Hips at Risk of Dislocation.
Proximal Femoral Guided Growth (PFGG) is performed under general anesthesia with the patient in a supine position on a radiolucent table. The surgical field is prepared from the abdomen to the feet. Anatomical landmarks on the femur and femoral neck are marked to guide the procedure. A smooth guidewire (4.0-7.0 mm) is introduced parallel to the table and advanced to the lateral quarter of the femoral neck. A 1-2 cm incision is made along the lateral femur, allowing access to the vastus lateralis muscle. Fluoroscopic control is used to ensure precise guidewire placement in the proximal femoral epiphysis in both anteroposterior (AP) and lateral views. The lateral cortex is drilled, and a fully threaded cannulated screw is inserted, ensuring at least three threads reach the epiphysis for effective growth modulation. Final fluoroscopic verification is performed to confirm proper screw placement and rule out joint penetration. Continuous fluoroscopy is used if necessary. The guidewire is r
Also known as: Guided Growth Surgery, Proximal Femoral Epiphysiodesis, Proximal Femoral Hemiepiphysiodesis
Both groups will receive standard prophylactic treatment for HRD, which consists of soft tissue release procedures based on clinical indication and functional level (GMFCS classification): Adductor Tenotomy - Percutaneous or open technique, depending on contracture severity. Psoas Tenotomy - Intrapelvic approach for GMFCS levels I-III and IV (ambulatory). Lesser trochanter approach for GMFCS levels IV-V (non-ambulatory). Additional tenotomies may be performed as needed, targeting muscles contributing to hip displacement and contractures. Botulinum toxin type A may be administered to specific muscle groups if clinically indicated. Postoperative immobilization includes: Hip abduction wedge Knee immobilizers in extension Ankle-foot orthoses (AFOs), based on individual patient needs The goal of this intervention is to reduce spastic muscle imbalance, improve hip stability, and delay or prevent hip dislocation in children with spastic CP and HRD.
Migration percentage (MP). Radiological
Percentage of the femoral head lateral to Perkins line on standardized AP pelvic radiograph. Unit of Measure: Percentage (%)
Time frame: Pre-surgery; 3 weeks; 6, 12, 18, and 24 months post-surgery
Pelvic Obliquity (PO). Radiological
Angle between the horizontal line and the line joining both iliac crests on AP pelvic radiograph. Unit of Measure: Degrees (°)
Time frame: Pre-surgery; 3 weeks; 6, 12, 18, and 24 months post-surgery.
Migration Percentage Adjusted for Pelvic Obliquity (PAMP). Radiological
Modified MP accounting for pelvic tilt, measured on AP pelvic radiograph. Unit of Measure: Percentage (%)
Time frame: Pre-surgery; 3 weeks; 6, 12, 18, and 24 months post-surgery.
Acetabular Index (AI). Radiological
Angle formed between Hilgenreiner's line and a line along the acetabular roof. Unit of Measure: Degrees (°)
Time frame: Pre-surgery; 3 weeks; 6, 12, 18, and 24 months post-surgery.
Center-Edge Angle (CEA). Radiological
Angle between vertical line through femoral head center and a line to lateral acetabular edge. Unit of Measure: Degrees (°)
Time frame: Pre-surgery; 3 weeks; 6, 12, 18, and 24 months post-surgery.
Hilgenreiner Epiphyseal Angle (HEA). Radiological
Angle between Hilgenreiner's line and a line along the proximal femoral physis. Unit of Measure: Degrees (°)
Time frame: Pre-surgery; 3 weeks; 6, 12, 18, and 24 months post-surgery.
Patient characteristics. Age
Chronological age of the patient at the time of surgery. Unit of measure: years
Time frame: At time of surgery
Patient characteristics. Sex
Biological sex of participant. Unit of Measure: Male/Female
Time frame: Pre-surgery
Patient characteristics. Gross Motor Function Classification System level (GMFCS)
GMFCS level will be recorded to classify gross motor function. The GMFCS has five levels (I to V), with higher levels indicating more severe motor impairment. Unit of measure: scale (I to V)
Time frame: Pre-surgery
Patient characteristics. Weight
Weight of the patient measured using a calibrated scale during the pre-surgical evaluation. Unit of measure: kilograms (kg)
Time frame: Pre-surgery
Patient characteristics. Orthopedic comorbidities
Presence or absence of orthopedic comorbidities such as scoliosis and knee flexion contractures will be assessed.
Time frame: Pre-surgery
Patient characteristics. Respiratory disorders or gastrointestinal issues
Presence or absence of relevant medical comorbidities, including epilepsy, respiratory disorders (e.g., obstructive sleep apnea, tracheostomy), and gastrointestinal disorders (e.g., gastrostomy), will be recorded.
Time frame: Pre-surgery
Patient characteristics. Medication use
Current use of any medication will be recorded as a categorical variable (yes/no), along with medication type if applicable.
Time frame: Pre-surgery
Clinical variables. Pain
Pain will be assessed using the Visual Analog Scale (VAS), a 10-cm horizontal line ranging from "no pain" to "worst imaginable pain." Higher scores indicate greater pain intensity. Unit of measure: scale (0-10)
Time frame: Immediately after surgery; 3 and 6 weeks; 6, 12, 18, and 24 months post-surgery
Clinical variables. Analgesic needs
Analgesic requirements will be recorded based on caregiver reports. Categorical: first-line analgesics (e.g., Ibuprofen, Paracetamol \[Acetaminophen\], Metamizole), second-line analgesics (e.g., mild opioids like Tramadol), or third-line analgesics (e.g., strong opioids such as morphine and fentanyl).
Time frame: Immediately after surgery; 3 and 6 weeks; 6, 12, 18, and 24 months post-surgery
Clinical variables. Hip abduction in flexion
Hip abduction in flexion will be measured in degrees during standardized physical examination. Unit of Measure: Degrees (º)
Time frame: Pre-surgery; at 6 weeks, 6 months, 12, 18, and 24 months
Clinical variables. Hip abduction in extension
Hip abduction in extension will be measured in degrees during standardized physical examination. Unit of Measure: Degrees (º)
Time frame: Pre-surgery; at 6 weeks, 6 months, 12, 18, and 24 months
Clinical variables. Hip flexion contracture >20°
Presence or absence of hip flexion contracture greater than 20 degrees will be recorded during physical examination. Yes/no
Time frame: Pre-surgery; at 6 weeks, 6 months, 12, 18, and 24 months
Clinical variables. Galeazzi sign
The Galeazzi sign will be assessed to detect femoral shortening as a clinical indicator of limb length discrepancy. Presence or absence will be recorded.
Time frame: Pre-surgery; at 6 weeks, 6 months, 12, 18, and 24 months
Clinical variables. Pelvic obliquity
Pelvic obliquity will be assessed clinically during physical examination and recorded as present or absent.
Time frame: Pre-surgery; at 6 weeks, 6 months, 12, 18, and 24 months
Functional variables
The Caregiver Priorities and Child Health Index of Life with Disabilities (CPCHILD) questionnaire will be completed. It is a validated measure of health-related quality of life for children with severe disabilities. Units on a scale (0-100; higher = better)
Time frame: Pre-surgery; 12 and 24 months
Concomitant treatment. Physiotherapy Frequency Per Week
Frequency of physiotherapy: Number of Physiotherapy Sessions per Week. Sessions per week.
Time frame: At 6 weeks; 6, 12, 18, and 24 months
Concomitant treatment. Orthoses Use
Use of orthoses: Number of hours per day the participant uses orthotic devices (e.g., hip abduction orthoses, scoliosis braces. Unit of Measure: Hours per day.
Time frame: At 6 weeks; 6, 12, 18, and 24 months
Concomitant treatment. Weight-Bearing Activity Time
Time Spent in Weight-Bearing Activities per Day. Unit of Measure: Minutes per day.
Time frame: At 6 weeks; 6, 12, 18, and 24 months
Concomitant treatment. Participation in Complementary Therapies
Participation in Complementary Therapies such as Hydrotherapy, hippotherapy, or other specified therapies. Unit of Measure: Yes/No.
Time frame: At 6 weeks; 6, 12, 18, and 24 months
Safety variables and parameters. Clinical complications
Wound dehiscence, hematoma, superficial or deep infection. New symptoms not present before surgery will also be evaluated, such as pain, hip mobility limitations or stiffness, insomnia, constipation, irritability, etc. Unit of Measure of all the above: Participants
Time frame: Immediately after surgery; 3 weeks; 6 weeks; 6 months; 12 months; 18 months; 24 months post-surgery
Safety variables and parameters. Radiological complications
Loosening of epiphyseal screws, peri-implant fracture, implant breakage, progression of hip displacement, avascular necrosis of the femoral head, chondrolysis, etc. Unit of Measure: Number of participants
Time frame: Immediately after surgery; 3 weeks; 6 weeks; 6 months; 12 months; 18 months; 24 months post-surgery
Safety variables and parameters. Functional complications
Intolerance to sitting, supine or lateral positioning, difficulty in perineal care, hygiene, or dressing. Unit of Measure of all the above: Participants
Time frame: Immediately after surgery; 3 weeks; 6 weeks; 6 months; 12 months; 18 months; 24 months post-surgery
Safety variables and parameters. Clavien-Dindo-Sink surgical complications classification
Complications will be classified according to the modified Clavien-Dindo-Sink surgical complications classification. Unit of Measure: Grade (Ordinal)
Time frame: Immediately after surgery; 3 weeks; 6 weeks; 6 months; 12 months; 18 months; 24 months post-surgery
Other variables. Surgical time
Measured from skin incision to closure, quantified in minutes
Time frame: Perioperative (intraoperative)
Other variables. Postoperative hospital stay
Measured in days, with the day of surgery as day 0.
Time frame: From surgery to discharge
Other variables. Time to comfortable wheelchair sitting
Number of days until the patient can sit comfortably in a wheelchair after surgery (day 0), as reported by primary caregivers.
Time frame: At 3 weeks post-surgery
Other variables. Time until pain-free perineal care and hygiene
Number of days until the patient can perform perineal care and hygiene without pain post-surgery (day 0), reported by primary caregivers during follow-up.
Time frame: Assessed at 3 weeks post-surgery
Other variables. Time to initiation of pain-free physiotherapy
Number of days from the surgical intervention (day 0) until the patient can begin physiotherapy without pain, as reported by primary caregivers during follow-up visits.
Time frame: Assessed at 3 weeks post-surgery
Plan to share: Yes — Participant data will be processed in accordance with current data protection legislation, including Organic Law 3/2018, of December 5, on Data Protection and Digital Rights, and the European Regulation (EU) 2016/679 (GDPR). This means that: The data controller is the Sponsor: SEOP Neuro-Orthopedics Working Group (Spanish Society of Pediatric Orthopedics). Data will be shared among study centers for statistical purposes only. Personal information is stored in medical records. Data will not leave the EU and will remain confidential. Patients may exercise their data rights and file complaints. Patients' names will not appear in any publications.
Supporting information: Study protocol, Statistical analysis plan
Time frame: Individual participant data and supporting documentation (Study Protocol and Statistical Analysis Plan) will be available beginning 6 months after the publication of the primary results and will remain accessible for 5 years. Data access will be limited to approved researchers under controlled conditions for statistical purposes only.
Access criteria: The data controller is the Sponsor: SEOP Group (Sociedad Española de Ortopedia Pediátrica). Data will be shared among study centers for statistical purposes only. Each participant: personal information will be stored in their medical record. Only the principal investigator and collaborators will be able to identify participants, as they will manage the database linking the assigned codes to each individual. Only health authorities or the Ethics Committee will have access to this information, ensuring confidentiality.
Started Oct 2024 (actual). Primary completion is estimated for Dec 2025, 14 months after the start.
Of 906 non-industry interventional studies with no phase under Cerebral Palsy, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 31. This study's planned 14 months is above that.
Counting every sponsor, half of 925 studies reached it within 12 months; a quarter within 5 and three quarters within 31.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.